AnHorn Medicines has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration and Index Case designation from Taiwan’s Center for Drug Evaluation for AH-008, a candidate for preventing chemotherapy-induced peripheral neuropathy.

• Regulatory Status: AH-008 received FDA IND clearance and Taiwan CDE Index Case designation, enabling progression towards human clinical trials.
• Indication: AH-008 is being developed as a preventive therapy for chemotherapy-induced peripheral neuropathy (CIPN) and is designed to target the underlying mechanisms of chemotherapy-related nerve damage.
• Preclinical Data: AH-008 demonstrated neuroprotective effects across multiple chemotherapy-induced neuropathy models, preserving peripheral nerve integrity while maintaining chemotherapy efficacy in those studies.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.